Opiate antagonist implant and process for preparation therefor
OwnerLance L. Goobermaninventor
Life of this patent
Estimating the term…
Abstract
The present invention provides an opiate antagonist implant which is an admixture of an opiate antagonist, in either acid or base form, and a pharmaceutically acceptable carrier. The admixture is uniformly compressed into a subcutaneously implantable pellet which is effective to release levels of the opiate antagonist over desired amounts of time when subcutaneously implanted in a patient to effectively inhibit the effects of a number of addictive drugs.
Claims24
An opiate antagonist implant comprising an admixture of an opiate antagonist and a pharmaceutically acceptable carrier, said admixture being compressed into a subcutaneously implantable pellet, wherein said implantable pellet is effective to release said opiate antagonist over time when subcutaneously implanted in a patient.
A process of manufacturing an opiate antagonist implant comprising compressing a therapeutically effective amount of an opiate antagonist with a pharmaceutically acceptable carrier.
A process of manufacturing a naltrexone implant comprising the steps of:
- (a) providing a quantity of naltrexone;
- (b) providing a pharmaceutically acceptable carrier;
- (c) admixing said pharmaceutically acceptable carrier and said naltrexone in a ratio of approximately 15 grams of said naltrexone for approximately every one gram of said pharmaceutically acceptable carrier;
- (d) triturating the admixture of step (c);
- (e) applying uniform pressure to the triturated admixture of step (d) in order to obtain a naltrexone implant in the form of a firm pellet.
A process of manufacturing a naltrexone implant comprising the steps of:
- (a) providing a quantity of naltrexone HCL;
- (b) providing a quantity of water;
- (c) admixing said quantity of water with said quantity of naltrexone HCL in a ratio of approximately 3 ml of water for approximately every one gram of naltrexone HCL until a slurry is obtained;
- (d) providing a quantity of 10% sodium hydroxide solution;
- (e) admixing said quantity of 10% sodium hydroxide solution to said slurry of step (c) in the ratio of approximately 1 ml of sodium hydroxide for approximately every one gram of naltrexone HCL;
- (f) filtering off any liquid from said slurry to obtain a solid residue of naltrexone;
- (g) drying said residue of naltrexone for approximately 24 to approximately 72 hours at a constant temperature of 50° C. (120° F.);
- (h) providing a pharmaceutically acceptable carrier;
- (i) admixing said pharmaceutically acceptable carrier and said naltrexone in a ratio of approximately 15 grams of said naltrexone for approximately every one gram of said pharmaceutically acceptable carrier;
- (j) triturating said admixture of step (i), and (k) applying uniform pressure to said triturated admixture of step (j) in order to obtain a naltrexone implant in the form of a firm pellet.
A method of treating an opiate addicted patient for opiate addiction comprising administering subcutaneously an opiate antagonist implant comprising an opiate antagonist implant comprising an admixture of an opiate antagonist and a pharmaceutically acceptable carrier, said admixture being compressed into a subcutaneously implantable pellet, wherein said implantable pellet is effective to release levels of said opiate antagonist over time when subcutaneously implanted in a patient.
A method of using an opiate antagonist implant comprising an opiate antagonist implant comprising an admixture of an opiate antagonist and a pharmaceutically acceptable carrier, said admixture being compressed into a subcutaneously implantable pellet, wherein said implantable pellet is effective to release levels of said opiate antagonist over time when subcutaneously implanted in a patient by subcutaneously implanting said implant in a patient in need thereof.
Dependencies are inferred from the claim text.